2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

2:30PM-4:00PM: Abstract Number: 2042

Pancreatitis Subtypes Survey in 852 Childhood-Onset Systemic Lupus Erythematosus Patients: A Multicenter Cohort

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2083

Predictors of Health Perceptions Among Women with Lupus

ARHP II: Lupus

2:30PM-4:00PM: Abstract Number: 2003

Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2004

Procoagulant Property of a Novel Patient-Derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody That Binds to Beta 2 Glycoprotein Domain I but Not to Total Beta 2 Glycoprotein I Molecule

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2054

Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2001

Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2024

Replacing Radiographic Sacroiliitis By Structural Lesions on MRI of the Sacroiliac Joints in Two Early Axial Spa Cohorts: What Is the Impact on the Classification of Patients According to the ASAS Axial Spa Criteria?

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2078

Reserve Capacity: Explaining the Link Between Socioeconomic Status and Depression/Anxiety Among Patients with Systemic Lupus Erythematosus

ARHP II: Lupus

2:30PM-4:00PM: Abstract Number: 2037

Rheumatic Manifestations May be the First Clinical Presentation of Arterial Calcification Due to CD73 Deficiency

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2051

Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

2:30PM-4:00PM: Abstract Number: 2019

Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors

Epidemiology and Public Health II: RA and Lifestyle Factors

2:30PM-4:00PM: Abstract Number: 2018

Sodium Chloride Consumption, Together with Smoking, Is Associated with ACPA Positivity

Epidemiology and Public Health II: RA and Lifestyle Factors

2:30PM-4:00PM: Abstract Number: 2040

T Follicular Helper like CD4+CXCR5+pd-1+ Cells and T Follicular Helper like Type 2 Cells Subsets Are Increased in IgG4-Related Disease Patients

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2015

Targeting Non-Canonical NF-Kappa B Signaling Inhibits Angiogenesis in a Novel 3D Model of Rheumatoid Arthritis Synovial Angiogenesis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

2:30PM-4:00PM: Abstract Number: 2080

Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers

ARHP II: Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].